IL-6 stabilizes twist and enhances tumor cell motility in head and neck cancer cells through activation of casein kinase 2

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Su, Ying Wen ^a,b   Xie, Tong Xin ^b   Sano, Daisuke ^b   Myers, Jeffrey N ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASEIN KINASE II; INTERLEUKIN 6; TRANSCRIPTION FACTOR TWIST; NUCLEAR PROTEIN; TWIST1 PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL MOTILITY; CONTROLLED STUDY; ENZYME ACTIVATION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN STABILITY; SQUAMOUS CELL CARCINOMA; UPREGULATION; GENE EXPRESSION REGULATION; HEAD AND NECK TUMOR; METABOLISM; METASTASIS; PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WOUND HEALING;

CARCINOMA, SQUAMOUS CELL; CASEIN KINASE II; CELL LINE, TUMOR; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; INTERLEUKIN-6; NEOPLASM METASTASIS; NUCLEAR PROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TWIST TRANSCRIPTION FACTOR; WOUND HEALING;

EID: 79955780958     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0019412     Document Type: Article

References (50)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
2. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, et al. (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357: 1705-1715.
3. Schultz JD, Bran G, Anders C, Sadick H, Faber A, et al. (2010) Induction chemotherapy with TPF (Docetaxel, Carboplatin and Fluorouracil) in the treatment of locally advanced squamous cell carcinoma of the head and neck. Oncol Rep 24: 1213-1216.
4. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, et al. (2008) Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 10: 295-305.
5. Kwok WK, Ling MT, Lee TW, Lau TC, Zhou C, et al. (2005) Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res 65: 5153-5162.
6. Hosono S, Kajiyama H, Terauchi M, Shibata K, Ino K, et al. (2007) Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients. Br J Cancer 96: 314-320.
7. Ou DL, Chien HF, Chen CL, Lin TC, Lin LI, (2008) Role of Twist in head and neck carcinoma with lymph node metastasis. Anticancer Res 28: 1355-1359.
8. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, et al. (2004) Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117: 927-939.
9. Gitelman I, (1997) Twist protein in mouse embryogenesis. Dev Biol 189: 205-214.
10. Demontis S, Rigo C, Piccinin S, Mizzau M, Sonego M, et al. (2006) Twist is substrate for caspase cleavage and proteasome-mediated degradation. Cell Death Differ 13: 335-345.
11. Firulli BA, Krawchuk D, Centonze VE, Vargesson N, Virshup DM, et al. (2005) Altered Twist1 and Hand2 dimerization is associated with Saethre-Chotzen syndrome and limb abnormalities. Nat Genet 37: 373-381.
12. Vichalkovski A, Gresko E, Hess D, Restuccia DF, Hemmings BA, (2010) PKB/AKT phosphorylation of the transcription factor Twist-1 at Ser42 inhibits p53 activity in response to DNA damage. Oncogene 29: 3554-3565.
13. Fuchs SY, Tappin I Ronai Z, (2000) Stability of the ATF2 transcription factor is regulated by phosphorylation and dephosphorylation. J Biol Chem 275: 12560-12564.
14. Allen C, Duffy S, Teknos T, Islam M, Chen Z, et al. (2007) Nuclear factor-kappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clin Cancer Res 13: 3182-3190.
15. Chen Z, Malhotra PS, Thomas GR, Ondrey FG, Duffey DC, et al. (1999) Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 5: 1369-79.
16. Schafer ZT, Brugge JS, (2007) IL-6 involvement in epithelial cancers. J Clin Invest 117: 3660-3663.
17. Dranoff G, (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4: 11-22.
18. Duffy SA, Taylor JM, Terrell JE, Islam M, Li Y, et al. (2008) Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 113: 750-757.
19. Colomiere M, Ward AC, Riley C, Trenerry MK, Cameron-Smith D, et al. (2009) Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer 100: 134-144.
20. Sullivan NJ, Sasser AK, Axel AE, Vesuna F, Raman V, et al. (2009) Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 28: 2940-2947.
21. Bromberg J, Wang TC, (2009) Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 15: 79-80.
22. Piazza FA, Ruzzene M, Gurrieri C, Montini B, Bonanni L, et al. (2006) Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood 108: 1698-1707.
23. Pinna LA, (2002) Protein kinase CK2: a challenge to canons. J Cell Sci 115: 3873-3878.
24. Lou DY, Dominguez I, Toselli P, Landesman-Bollag E, O'Brien C, et al. (2008) The alpha catalytic subunit of protein kinase CK2 is required for mouse embryonic development. Mol Cell Biol 28: 131-139.
25. Buchou T, Vernet M, Blond O, Jensen HH, Pointu H, et al. (2003) Disruption of the regulatory beta subunit of protein kinase CK2 in mice leads to a cell-autonomous defect and early embryonic lethality. Mol Cell Biol 23: 908-915.
26. Xu X, Toselli PA, Russell LD, Seldin DC, (1999) Globozoospermia in mice lacking the casein kinase II alpha' catalytic subunit. Nat Genet 23: 118-121.
27. St-Denis NA, Litchfield DW, (2009) Protein kinase CK2 in health and disease: From birth to death: the role of protein kinase CK2 in the regulation of cell proliferation and survival. Cell Mol Life Sci 66: 1817-1829.
28. Kato T Jr, Delhase M, Hoffmann A, Karin M, (2003) CK2 is a C-terminal IkappaB kinase responsible for NF-kappaB activation during the UV response. Mol Cell 12: 829-839.
29. Scaglioni PP, Yung TM, Choi SC, Baldini C, Konstantinidou G, et al. (2008) CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor. Mol Cell Biochem 316: 149-154.
30. Ahmed K, Gerber DA, Cochet C, (2002) Joining the cell survival squad: an emerging role for protein kinase CK2. Trends Cell Biol 12: 226-230.
31. Charoenrat P, Rusch V, Talbot SG, Sarkaria I, Viale A, et al. (2004) Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung. Clin Cancer Res 10: 5792-5803.
32. Gapany M, Faust RA, Tawfic S, Davis A, Adams GL, et al. (1995) Association of elevated protein kinase CK2 activity with aggressive behavior of squamous cell carcinoma of the head and neck. Mol Med 1: 659-666.
33. Ji H, Wang J, Nika H, Hawke D, Keezer S, et al. (2009) EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-catenin from beta-catenin and transactivation of beta-catenin. Mol Cell 36: 547-559.
34. Allende JE, Allende CC, (1995) Protein kinases. 4. Protein kinase CK2: an enzyme with multiple substrates and a puzzling regulation. FASEB J 9: 313-323.
35. Cheng GZ, Zhang WZ, Sun M, Wang Q, Coppola D, et al. (2008) Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J Biol Chem 283: 14665-14673.
36. Lo HW, Hsu SC, Xia W, Cao X, Shih JY, et al. (2007) Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res 67: 9066-9076.
37. Holmberg CI, Tran SE, Eriksson JE, Sistonen L, (2002) Multisite phosphorylation provides sophisticated regulation of transcription factors. Trends Biochem Sci 27: 619-627.
38. Shinriki S, Jono H, Ota K, Ueda M, Kudo M, et al. (2009) Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin Cancer Res 15: 5426-5434.
39. Brown MS, Diallo OT, Hu M, Ehsanian R, Yang X, et al. (2010) CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules. Clin Cancer Res 16: 2295-2307.
40. Bourguignon LY, Wong G, Earle C, Krueger K, Spevak CC, (2010) Hyaluronan-CD44 interaction promotes c-Src-mediated Twist signaling, microRNA-10b expression, and RhoA/RhoC up-regulation, leading to Rho-kinase-associated cytoskeleton activation and breast tumor cell invasion. J Biol Chem 285: 36721-36735.
41. Singh S, Gramolini AO, (2009) Characterization of sequences in human TWIST required for nuclear localization. BMC Cell Biol 10: 47.
42. Wallerand H, Robert G, Pasticier G, Ravaud A, Ballanger P, et al. (2010) The epithelial-mesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers. Urol Oncol 28: 473-479.
43. Wang G, Unger G, Ahmad KA, Slaton JW, Ahmed K, (2005) Downregulation of CK2 induces apoptosis in cancer cells-a potential approach to cancer therapy. Mol Cell Biochem 274: 77-84.
44. Trembley JH, Chen Z, Unger G, Slaton J, Kren BT, et al. (2010) Emergence of protein kinase CK2 as a key target in cancer therapy. Biofactors 36: 187-195.
45. Seldin DC, Leder P, (1995) Casein kinase II alpha transgene-induced murine lymphoma: relation to theileriosis in cattle. Science 267: 894-897.
46. Landesman-Bollag E, Romieu-Mourez R, Song DH, Sonenshein GE, Cardiff RD, et al. (2001) Protein kinase CK2 in mammary gland tumorigenesis. Oncogene 20: 3247-3257.
47. Solares AM, Santana A, Baladron I, Valenzuela C, Gonzalez CA, et al. (2009) Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies. BMC Cancer 9: 146.
48. Zhou G, Xie TX, Zhao M, Jasser SA, Younes MN, et al. (2008) Reciprocal negative regulation between S100A7/psoriasin and beta-catenin signaling plays an important role in tumor progression of squamous cell carcinoma of oral cavity. Oncogene 27: 3527-3238.
49. Pagano MA, Meggio F, Ruzzene M, Andrzejewska M, Kazimierczuk Z, et al. (2004) 2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. Biochem Biophys Res Commun 321: 1040-1044.
50. Liang CC, Park AY, Guan JL, (2007) In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protoc 2: 329-333.